Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc (NY: CYBN )

10.38 +0.13 (+1.27%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
38 39 Next >
Psychedelic & Marijuana Drug Stocks Continued To Decline Last Week
An update on the stock performances of the 13 clinical-stage psychedelic and marijuana drug companies with the largest market capitalizations.tttttttttt 
Via Talk Markets
Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 17, 2022
GAINERS: Mindset Pharma (OTC: 
Via Benzinga
Cybin Chopra Foundation Team To Advance Psychedelics In Mental Health
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Aegis Virtual Conference
Via Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN), Chopra Foundation Team to Advance Psychedelics in Mental Health
Via Investor Brand Network
Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And Education
Psychedelics-focused biotech company Cybin Inc. (NYSE:CYBN) ... 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 15, 2022
GAINERS: Mind Medicine (NASDAQ: 
Via Benzinga
Cybin to Participate in Aegis Virtual Conference on February 24, 2022
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), The Chopra Foundation Partner to Uncover Potential of Psychedelic Therapies in Mental Health
Via Investor Brand Network
Cybin Turning Psychedelics-to-Therapeutics(TM) Vision Into Reality
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Turning Psychedelics-to-Therapeutics(TM) Vision into Reality
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From February 14, 2022
GAINERS: Wellbeing Digital (OTC: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Working on Turning Psychedelics-to-Therapeutics(TM) Vision into Reality
Via Investor Brand Network
Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event
Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psy... 
Via Benzinga
Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ... 
Via Benzinga
Mind Medicine, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI... 
Via Benzinga
Allied, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 7.39% at $1.89 
Via Benzinga
Cybin Granted US Patent Covering Lead Proprietary Compound
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From February 9, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 14.29% at $5.76 
Via Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound for Treatment of Anxiety Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
Psychedelics company Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced that the U.S. Patent and Trademark Office  has granted U.S. patent 11,242,318 to the company’s investigational deuterated... 
Via Benzinga
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.